The Use of Eculizumab in Tacrolimus-Induced Thrombotic Microangiopathy
Drug-induced thrombotic microangiopathy (DITMA) is a secondary cause of thrombotic microangiopathy and a potentially fatal inflammatory disease. DITMA has been attributed to a variety of drugs, particularly chemotherapeutic and immunosuppressive agents. Prompt diagnosis is critical for survival and...
Saved in:
Main Authors: | Jihad Ben Gabr MD (Author), Hiba Bilal MD (Author), Kanish Mirchia MD (Author), Andras Perl MD, PhD (Author) |
---|---|
Format: | Book |
Published: |
SAGE Publishing,
2020-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eculizumab for bevacizumab induced thrombotic microangiopathy: A case report
by: Mihriban İnözü, et al.
Published: (2022) -
Use of Eculizumab in Pediatric Patients With Transplant Associated Thrombotic Microangiopathy
by: Laura Gomez-Ganda, et al.
Published: (2021) -
A Case Report of Quinine-Induced Thrombotic Microangiopathy Successfully Treated With Eculizumab
by: Jun Yen Ng BMedSci (Hons), et al.
Published: (2024) -
Carfilzomib-Induced Thrombotic Microangiopathy Treated with Eculizumab: A Case Report and Rapid Literature Review
by: Federica Pallotti, et al.
Published: (2022) -
Educational Case: Differentiating Thrombotic Thrombocytopenic Purpura From Other Thrombotic Microangiopathies and Potential Role of the Spleen
by: Meredith M. Nichols MD, et al.
Published: (2021)